-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎WuXi AppTec Content Team Editor Recently, AstraZeneca launched a Phase 2 clinical trial for its PD-1/ The TIGIT bispecific antibody AZD2936 was evaluated
for its efficacy and safety in the treatment of patients with stage 3 unresectable or stage 4 non-small cell lung cancer (NCSLC).
TIGIT is an immune checkpoint protein expressed mainly on the surface of T cells and natural killer cells (NK cells), and its role in tumor immunosuppression is similar
to PD-1/PD-L1.
Studies have found that blocking the immunosuppression produced by TIGIT binding to ligands can relieve the inhibition and depletion of T cells and NK cells, and then promote the anti-tumor effect
mediated by T cells and NK cells.
Simultaneous blockade of PD-1 and TIGIT is expected to exert a synergistic anti-tumor effect
.
AZD2936 is a PD-1/TIGIT bispecific antibody
developed by AstraZeneca based on Compugen's anti-TIGIT antibody COM902.
Compugen is a clinical-stage drug discovery and development company that aims to identify new drug targets and new biological pathways and develop new therapeutics
in the field of cancer immunotherapy using its broadly applicable predictive computational discovery platform.
COM902 is a high-affinity anti-TIGIT antibody developed by Compugen and is currently in Phase 1 clinical stage
.
Image source: 123RF
In 2018, Compugen signed an agreement with AstraZeneca, Grant AstraZeneca an exclusive license
to use its anti-TIGIT monoclonal antibody (including COM902) for the development of bispecific antibody and multispecific antibody products.
Among them, AstraZeneca will be responsible for the research, development and commercialization
of the corresponding products.
Compugen will receive a milestone payment
of $7.
5 million from AstraZeneca after completing the first patient dosing in this Phase 2 study.
The clinical trial is a Phase 1/2 open-label dose-escalation and scale-up study of 147 patients to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of AZD2936 in patients with advanced or metastatic NCSLC, and is expected to be completed
in July 2025.
Dr.
Anat Cohen-Dayag, President and CEO of Compugen, said, "AstraZeneca's advancement of AZD2936 into Phase 2 clinical trials gives us confidence
in the therapeutic potential of the TIGIT antibody COM902.
Like COM902, AZD2936 has the potential to
enhance antitumor activity while reducing Fc effector function.
We believe this is the best design possible and look forward to it making a difference
in the clinic.
”
for its efficacy and safety in the treatment of patients with stage 3 unresectable or stage 4 non-small cell lung cancer (NCSLC).
TIGIT is an immune checkpoint protein expressed mainly on the surface of T cells and natural killer cells (NK cells), and its role in tumor immunosuppression is similar
to PD-1/PD-L1.
Studies have found that blocking the immunosuppression produced by TIGIT binding to ligands can relieve the inhibition and depletion of T cells and NK cells, and then promote the anti-tumor effect
mediated by T cells and NK cells.
Simultaneous blockade of PD-1 and TIGIT is expected to exert a synergistic anti-tumor effect
.
AZD2936 is a PD-1/TIGIT bispecific antibody
developed by AstraZeneca based on Compugen's anti-TIGIT antibody COM902.
Compugen is a clinical-stage drug discovery and development company that aims to identify new drug targets and new biological pathways and develop new therapeutics
in the field of cancer immunotherapy using its broadly applicable predictive computational discovery platform.
COM902 is a high-affinity anti-TIGIT antibody developed by Compugen and is currently in Phase 1 clinical stage
.
Image source: 123RF
In 2018, Compugen signed an agreement with AstraZeneca, Grant AstraZeneca an exclusive license
to use its anti-TIGIT monoclonal antibody (including COM902) for the development of bispecific antibody and multispecific antibody products.
Among them, AstraZeneca will be responsible for the research, development and commercialization
of the corresponding products.
Compugen will receive a milestone payment
of $7.
5 million from AstraZeneca after completing the first patient dosing in this Phase 2 study.
The clinical trial is a Phase 1/2 open-label dose-escalation and scale-up study of 147 patients to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of AZD2936 in patients with advanced or metastatic NCSLC, and is expected to be completed
in July 2025.
Dr.
Anat Cohen-Dayag, President and CEO of Compugen, said, "AstraZeneca's advancement of AZD2936 into Phase 2 clinical trials gives us confidence
in the therapeutic potential of the TIGIT antibody COM902.
Like COM902, AZD2936 has the potential to
enhance antitumor activity while reducing Fc effector function.
We believe this is the best design possible and look forward to it making a difference
in the clinic.
”
WuXi AppTec provides integrated, end-to-end new drug development and manufacturing services to the global biopharmaceutical industry, covering chemical drug development and manufacturing, biological research, preclinical testing and clinical trial development, cell and gene therapy development, testing and manufacturing
.
If you have relevant business needs, please click the picture below to fill in the specific information
.
